Global Osteoarthritis Therapeutics Market

Osteoarthritis Therapeutics Comprehensive Study by Type (Primary osteoarthritis, Secondary osteoarthritis), Application (Lifestyle changes. Exercise, Pain relief medicines, Supportive treatments, Surgery, Complementary and alternative therapies), Drug Type (Prescription Drugs, Over-the-Counter Drugs), Route of Administration (Parenteral Route, Topical Route, Oral Route), Sales Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Anatomy (Knee Osteoarthritis, Hip Osteoarthritis, Hand Osteoarthritis, Small Joint Osteoarthritis, Shoulder Osteoarthritis, Other) Players and Region - Global Market Outlook to 2030

Osteoarthritis Therapeutics Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 9.05%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Osteoarthritis Therapeutics
Osteoarthritis is a primary cause of pain & disability among adults with a current frequency of ~15% and a predicted prevalence of ~35% by 2030. It can affect any joint, but mostly the knees, hips, lower back and neck and small joints of fingers. It is a chronic (long-term) disease for which there is no cure. As per an estimation, over 30 million adults in the United States have osteoarthritis. Moreover, one in four adults will develop symptoms of hip osteoarthritis by age 85 and one in 12 people aged over 60 have hand osteoarthritis. The use of prescription and over-the-counter medications to reduce pain and decrease inflammation has increased rapidly since last few years. In addition, the government support for research & development for osteoarthritis treatment will create growth opportunities for the global osteoarthritis treatment market.

AttributesDetails
Study Period2018-2030
Base Year2023
High Growth MarketAsia Pacific
UnitValue (USD Million)
CAGR9.05%


The market is fragmented by numerous key players who have the bargaining power high in the global osteoarthritis therapeutics market as the market is dominated by several key players. The intensity of rivalry appears to be high in this market as competitors are numerous and the drugs are undifferentiated. Analyst at AMA Research estimates that United States and European Players will contribute the maximum growth to Global Osteoarthritis Therapeutics market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Sanofi (France), Horizon Therapeutics PLC (Ireland), Johnson & Johnson (United States), GlaxoSmithKline PLC (United Kingdom), Bayer AG (Germany), Abbott (United States), Pfizer, Inc. (United States), Eli Lilly (United States), Anika Therapeutics, Inc. (United States) and Novartis AG (Switzerland) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Ferring Pharmaceuticals (Switzerland), Bioventus (United States), Zimmer Biomet Holdings, Inc. (United States), Fidia Farmaceutici s.p.a. (Italy), Pharmed Limited (India), Hanmi Pharm. Co., Ltd. (Korea) and Laboratorio Reig Jofre (Spain).

Segmentation Overview
AMA Research has segmented the market of Global Osteoarthritis Therapeutics market by Type (Primary osteoarthritis and Secondary osteoarthritis), Application (Lifestyle changes. Exercise, Pain relief medicines, Supportive treatments, Surgery and Complementary and alternative therapies) and Region.



On the basis of geography, the market of Osteoarthritis Therapeutics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Europe region held largest market share in the year 2023. North America, on the other hand, stood as the second largest market due to the presence of key companies in the region and high technological advancement. If we see Market by Drug Type, the sub-segment i.e. Prescription Drugs will boost the Osteoarthritis Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Route of Administration, the sub-segment i.e. Parenteral Route will boost the Osteoarthritis Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Sales Channel, the sub-segment i.e. Hospital Pharmacies will boost the Osteoarthritis Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Anatomy, the sub-segment i.e. Knee Osteoarthritis will boost the Osteoarthritis Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Personalized Medicines For Osteoarthritis

Market Growth Drivers:
Growing Occurrence Of Orthopedic Disorders, Adoption Of Pain Killer Medications To Avoid Surgical Procedures and Rising Number Of Sports Injuries

Challenges:
Adoption Of Non-Drug Pain Management Therapies

Restraints:
High Cost Associated With Drugs

Opportunities:
Growing Population Susceptible To Osteoarthritis and Collaborations For Product Development

Market Leaders and their expansionary development strategies
In December, 2023 Eli Lilly and Company announced the successful completion of its acquisition of POINT Biopharma Global Inc. a radiopharmaceutical company with a pipeline of clinical and preclinical stage radioligand therapies in development for the treatment of cancer.
In February 2020, FDA approves GlaxoSmithKline’s product named Voltaren Arthritis Pain for over-the-counter use in the United States. This product was developed to provide temporary relief of arthritis pain in the hand, wrist, elbow, foot, knee in adults (18 years and older).ankle or


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Osteoarthritis Therapeutics Manufacturer, Raw Material Suppliers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Primary osteoarthritis
  • Secondary osteoarthritis
By Application
  • Lifestyle changes. Exercise
  • Pain relief medicines
  • Supportive treatments
  • Surgery
  • Complementary and alternative therapies
By Drug Type
  • Prescription Drugs
  • Over-the-Counter Drugs

By Route of Administration
  • Parenteral Route
  • Topical Route
  • Oral Route

By Sales Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Anatomy
  • Knee Osteoarthritis
  • Hip Osteoarthritis
  • Hand Osteoarthritis
  • Small Joint Osteoarthritis
  • Shoulder Osteoarthritis
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Occurrence Of Orthopedic Disorders
      • 3.2.2. Adoption Of Pain Killer Medications To Avoid Surgical Procedures
      • 3.2.3. Rising Number Of Sports Injuries
    • 3.3. Market Challenges
      • 3.3.1. Adoption Of Non-Drug Pain Management Therapies
    • 3.4. Market Trends
      • 3.4.1. Personalized Medicines For Osteoarthritis
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Osteoarthritis Therapeutics, by Type, Application, Drug Type, Route of Administration, Sales Channel, Anatomy and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Osteoarthritis Therapeutics (Value)
      • 5.2.1. Global Osteoarthritis Therapeutics by: Type (Value)
        • 5.2.1.1. Primary osteoarthritis
        • 5.2.1.2. Secondary osteoarthritis
      • 5.2.2. Global Osteoarthritis Therapeutics by: Application (Value)
        • 5.2.2.1. Lifestyle changes. Exercise
        • 5.2.2.2. Pain relief medicines
        • 5.2.2.3. Supportive treatments
        • 5.2.2.4. Surgery
        • 5.2.2.5. Complementary and alternative therapies
      • 5.2.3. Global Osteoarthritis Therapeutics by: Drug Type (Value)
        • 5.2.3.1. Prescription Drugs
        • 5.2.3.2. Over-the-Counter Drugs
      • 5.2.4. Global Osteoarthritis Therapeutics by: Route of Administration (Value)
        • 5.2.4.1. Parenteral Route
        • 5.2.4.2. Topical Route
        • 5.2.4.3. Oral Route
      • 5.2.5. Global Osteoarthritis Therapeutics by: Sales Channel (Value)
        • 5.2.5.1. Hospital Pharmacies
        • 5.2.5.2. Retail Pharmacies
        • 5.2.5.3. Online Pharmacies
      • 5.2.6. Global Osteoarthritis Therapeutics by: Anatomy (Value)
        • 5.2.6.1. Knee Osteoarthritis
        • 5.2.6.2. Hip Osteoarthritis
        • 5.2.6.3. Hand Osteoarthritis
        • 5.2.6.4. Small Joint Osteoarthritis
        • 5.2.6.5. Shoulder Osteoarthritis
        • 5.2.6.6. Other
      • 5.2.7. Global Osteoarthritis Therapeutics Region
        • 5.2.7.1. South America
          • 5.2.7.1.1. Brazil
          • 5.2.7.1.2. Argentina
          • 5.2.7.1.3. Rest of South America
        • 5.2.7.2. Asia Pacific
          • 5.2.7.2.1. China
          • 5.2.7.2.2. Japan
          • 5.2.7.2.3. India
          • 5.2.7.2.4. South Korea
          • 5.2.7.2.5. Taiwan
          • 5.2.7.2.6. Australia
          • 5.2.7.2.7. Rest of Asia-Pacific
        • 5.2.7.3. Europe
          • 5.2.7.3.1. Germany
          • 5.2.7.3.2. France
          • 5.2.7.3.3. Italy
          • 5.2.7.3.4. United Kingdom
          • 5.2.7.3.5. Netherlands
          • 5.2.7.3.6. Rest of Europe
        • 5.2.7.4. MEA
          • 5.2.7.4.1. Middle East
          • 5.2.7.4.2. Africa
        • 5.2.7.5. North America
          • 5.2.7.5.1. United States
          • 5.2.7.5.2. Canada
          • 5.2.7.5.3. Mexico
  • 6. Osteoarthritis Therapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Sanofi (France)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Horizon Therapeutics PLC (Ireland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Johnson & Johnson (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. GlaxoSmithKline PLC (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bayer AG (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Abbott (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pfizer, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Eli Lilly (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Anika Therapeutics, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Novartis AG (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Osteoarthritis Therapeutics Sale, by Type, Application, Drug Type, Route of Administration, Sales Channel, Anatomy and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Osteoarthritis Therapeutics (Value)
      • 7.2.1. Global Osteoarthritis Therapeutics by: Type (Value)
        • 7.2.1.1. Primary osteoarthritis
        • 7.2.1.2. Secondary osteoarthritis
      • 7.2.2. Global Osteoarthritis Therapeutics by: Application (Value)
        • 7.2.2.1. Lifestyle changes. Exercise
        • 7.2.2.2. Pain relief medicines
        • 7.2.2.3. Supportive treatments
        • 7.2.2.4. Surgery
        • 7.2.2.5. Complementary and alternative therapies
      • 7.2.3. Global Osteoarthritis Therapeutics by: Drug Type (Value)
        • 7.2.3.1. Prescription Drugs
        • 7.2.3.2. Over-the-Counter Drugs
      • 7.2.4. Global Osteoarthritis Therapeutics by: Route of Administration (Value)
        • 7.2.4.1. Parenteral Route
        • 7.2.4.2. Topical Route
        • 7.2.4.3. Oral Route
      • 7.2.5. Global Osteoarthritis Therapeutics by: Sales Channel (Value)
        • 7.2.5.1. Hospital Pharmacies
        • 7.2.5.2. Retail Pharmacies
        • 7.2.5.3. Online Pharmacies
      • 7.2.6. Global Osteoarthritis Therapeutics by: Anatomy (Value)
        • 7.2.6.1. Knee Osteoarthritis
        • 7.2.6.2. Hip Osteoarthritis
        • 7.2.6.3. Hand Osteoarthritis
        • 7.2.6.4. Small Joint Osteoarthritis
        • 7.2.6.5. Shoulder Osteoarthritis
        • 7.2.6.6. Other
      • 7.2.7. Global Osteoarthritis Therapeutics Region
        • 7.2.7.1. South America
          • 7.2.7.1.1. Brazil
          • 7.2.7.1.2. Argentina
          • 7.2.7.1.3. Rest of South America
        • 7.2.7.2. Asia Pacific
          • 7.2.7.2.1. China
          • 7.2.7.2.2. Japan
          • 7.2.7.2.3. India
          • 7.2.7.2.4. South Korea
          • 7.2.7.2.5. Taiwan
          • 7.2.7.2.6. Australia
          • 7.2.7.2.7. Rest of Asia-Pacific
        • 7.2.7.3. Europe
          • 7.2.7.3.1. Germany
          • 7.2.7.3.2. France
          • 7.2.7.3.3. Italy
          • 7.2.7.3.4. United Kingdom
          • 7.2.7.3.5. Netherlands
          • 7.2.7.3.6. Rest of Europe
        • 7.2.7.4. MEA
          • 7.2.7.4.1. Middle East
          • 7.2.7.4.2. Africa
        • 7.2.7.5. North America
          • 7.2.7.5.1. United States
          • 7.2.7.5.2. Canada
          • 7.2.7.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Osteoarthritis Therapeutics: by Type(USD Million)
  • Table 2. Osteoarthritis Therapeutics Primary osteoarthritis , by Region USD Million (2018-2023)
  • Table 3. Osteoarthritis Therapeutics Secondary osteoarthritis , by Region USD Million (2018-2023)
  • Table 4. Osteoarthritis Therapeutics: by Application(USD Million)
  • Table 5. Osteoarthritis Therapeutics Lifestyle changes. Exercise , by Region USD Million (2018-2023)
  • Table 6. Osteoarthritis Therapeutics Pain relief medicines , by Region USD Million (2018-2023)
  • Table 7. Osteoarthritis Therapeutics Supportive treatments , by Region USD Million (2018-2023)
  • Table 8. Osteoarthritis Therapeutics Surgery , by Region USD Million (2018-2023)
  • Table 9. Osteoarthritis Therapeutics Complementary and alternative therapies , by Region USD Million (2018-2023)
  • Table 10. Osteoarthritis Therapeutics: by Drug Type(USD Million)
  • Table 11. Osteoarthritis Therapeutics Prescription Drugs , by Region USD Million (2018-2023)
  • Table 12. Osteoarthritis Therapeutics Over-the-Counter Drugs , by Region USD Million (2018-2023)
  • Table 13. Osteoarthritis Therapeutics: by Route of Administration(USD Million)
  • Table 14. Osteoarthritis Therapeutics Parenteral Route , by Region USD Million (2018-2023)
  • Table 15. Osteoarthritis Therapeutics Topical Route , by Region USD Million (2018-2023)
  • Table 16. Osteoarthritis Therapeutics Oral Route , by Region USD Million (2018-2023)
  • Table 17. Osteoarthritis Therapeutics: by Sales Channel(USD Million)
  • Table 18. Osteoarthritis Therapeutics Hospital Pharmacies , by Region USD Million (2018-2023)
  • Table 19. Osteoarthritis Therapeutics Retail Pharmacies , by Region USD Million (2018-2023)
  • Table 20. Osteoarthritis Therapeutics Online Pharmacies , by Region USD Million (2018-2023)
  • Table 21. Osteoarthritis Therapeutics: by Anatomy(USD Million)
  • Table 22. Osteoarthritis Therapeutics Knee Osteoarthritis , by Region USD Million (2018-2023)
  • Table 23. Osteoarthritis Therapeutics Hip Osteoarthritis , by Region USD Million (2018-2023)
  • Table 24. Osteoarthritis Therapeutics Hand Osteoarthritis , by Region USD Million (2018-2023)
  • Table 25. Osteoarthritis Therapeutics Small Joint Osteoarthritis , by Region USD Million (2018-2023)
  • Table 26. Osteoarthritis Therapeutics Shoulder Osteoarthritis , by Region USD Million (2018-2023)
  • Table 27. Osteoarthritis Therapeutics Other , by Region USD Million (2018-2023)
  • Table 28. South America Osteoarthritis Therapeutics, by Country USD Million (2018-2023)
  • Table 29. South America Osteoarthritis Therapeutics, by Type USD Million (2018-2023)
  • Table 30. South America Osteoarthritis Therapeutics, by Application USD Million (2018-2023)
  • Table 31. South America Osteoarthritis Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 32. South America Osteoarthritis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 33. South America Osteoarthritis Therapeutics, by Sales Channel USD Million (2018-2023)
  • Table 34. South America Osteoarthritis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 35. Brazil Osteoarthritis Therapeutics, by Type USD Million (2018-2023)
  • Table 36. Brazil Osteoarthritis Therapeutics, by Application USD Million (2018-2023)
  • Table 37. Brazil Osteoarthritis Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 38. Brazil Osteoarthritis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 39. Brazil Osteoarthritis Therapeutics, by Sales Channel USD Million (2018-2023)
  • Table 40. Brazil Osteoarthritis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 41. Argentina Osteoarthritis Therapeutics, by Type USD Million (2018-2023)
  • Table 42. Argentina Osteoarthritis Therapeutics, by Application USD Million (2018-2023)
  • Table 43. Argentina Osteoarthritis Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 44. Argentina Osteoarthritis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 45. Argentina Osteoarthritis Therapeutics, by Sales Channel USD Million (2018-2023)
  • Table 46. Argentina Osteoarthritis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 47. Rest of South America Osteoarthritis Therapeutics, by Type USD Million (2018-2023)
  • Table 48. Rest of South America Osteoarthritis Therapeutics, by Application USD Million (2018-2023)
  • Table 49. Rest of South America Osteoarthritis Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 50. Rest of South America Osteoarthritis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 51. Rest of South America Osteoarthritis Therapeutics, by Sales Channel USD Million (2018-2023)
  • Table 52. Rest of South America Osteoarthritis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 53. Asia Pacific Osteoarthritis Therapeutics, by Country USD Million (2018-2023)
  • Table 54. Asia Pacific Osteoarthritis Therapeutics, by Type USD Million (2018-2023)
  • Table 55. Asia Pacific Osteoarthritis Therapeutics, by Application USD Million (2018-2023)
  • Table 56. Asia Pacific Osteoarthritis Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 57. Asia Pacific Osteoarthritis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 58. Asia Pacific Osteoarthritis Therapeutics, by Sales Channel USD Million (2018-2023)
  • Table 59. Asia Pacific Osteoarthritis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 60. China Osteoarthritis Therapeutics, by Type USD Million (2018-2023)
  • Table 61. China Osteoarthritis Therapeutics, by Application USD Million (2018-2023)
  • Table 62. China Osteoarthritis Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 63. China Osteoarthritis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 64. China Osteoarthritis Therapeutics, by Sales Channel USD Million (2018-2023)
  • Table 65. China Osteoarthritis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 66. Japan Osteoarthritis Therapeutics, by Type USD Million (2018-2023)
  • Table 67. Japan Osteoarthritis Therapeutics, by Application USD Million (2018-2023)
  • Table 68. Japan Osteoarthritis Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 69. Japan Osteoarthritis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 70. Japan Osteoarthritis Therapeutics, by Sales Channel USD Million (2018-2023)
  • Table 71. Japan Osteoarthritis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 72. India Osteoarthritis Therapeutics, by Type USD Million (2018-2023)
  • Table 73. India Osteoarthritis Therapeutics, by Application USD Million (2018-2023)
  • Table 74. India Osteoarthritis Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 75. India Osteoarthritis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 76. India Osteoarthritis Therapeutics, by Sales Channel USD Million (2018-2023)
  • Table 77. India Osteoarthritis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 78. South Korea Osteoarthritis Therapeutics, by Type USD Million (2018-2023)
  • Table 79. South Korea Osteoarthritis Therapeutics, by Application USD Million (2018-2023)
  • Table 80. South Korea Osteoarthritis Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 81. South Korea Osteoarthritis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 82. South Korea Osteoarthritis Therapeutics, by Sales Channel USD Million (2018-2023)
  • Table 83. South Korea Osteoarthritis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 84. Taiwan Osteoarthritis Therapeutics, by Type USD Million (2018-2023)
  • Table 85. Taiwan Osteoarthritis Therapeutics, by Application USD Million (2018-2023)
  • Table 86. Taiwan Osteoarthritis Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 87. Taiwan Osteoarthritis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 88. Taiwan Osteoarthritis Therapeutics, by Sales Channel USD Million (2018-2023)
  • Table 89. Taiwan Osteoarthritis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 90. Australia Osteoarthritis Therapeutics, by Type USD Million (2018-2023)
  • Table 91. Australia Osteoarthritis Therapeutics, by Application USD Million (2018-2023)
  • Table 92. Australia Osteoarthritis Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 93. Australia Osteoarthritis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 94. Australia Osteoarthritis Therapeutics, by Sales Channel USD Million (2018-2023)
  • Table 95. Australia Osteoarthritis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 96. Rest of Asia-Pacific Osteoarthritis Therapeutics, by Type USD Million (2018-2023)
  • Table 97. Rest of Asia-Pacific Osteoarthritis Therapeutics, by Application USD Million (2018-2023)
  • Table 98. Rest of Asia-Pacific Osteoarthritis Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 99. Rest of Asia-Pacific Osteoarthritis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 100. Rest of Asia-Pacific Osteoarthritis Therapeutics, by Sales Channel USD Million (2018-2023)
  • Table 101. Rest of Asia-Pacific Osteoarthritis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 102. Europe Osteoarthritis Therapeutics, by Country USD Million (2018-2023)
  • Table 103. Europe Osteoarthritis Therapeutics, by Type USD Million (2018-2023)
  • Table 104. Europe Osteoarthritis Therapeutics, by Application USD Million (2018-2023)
  • Table 105. Europe Osteoarthritis Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 106. Europe Osteoarthritis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 107. Europe Osteoarthritis Therapeutics, by Sales Channel USD Million (2018-2023)
  • Table 108. Europe Osteoarthritis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 109. Germany Osteoarthritis Therapeutics, by Type USD Million (2018-2023)
  • Table 110. Germany Osteoarthritis Therapeutics, by Application USD Million (2018-2023)
  • Table 111. Germany Osteoarthritis Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 112. Germany Osteoarthritis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 113. Germany Osteoarthritis Therapeutics, by Sales Channel USD Million (2018-2023)
  • Table 114. Germany Osteoarthritis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 115. France Osteoarthritis Therapeutics, by Type USD Million (2018-2023)
  • Table 116. France Osteoarthritis Therapeutics, by Application USD Million (2018-2023)
  • Table 117. France Osteoarthritis Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 118. France Osteoarthritis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 119. France Osteoarthritis Therapeutics, by Sales Channel USD Million (2018-2023)
  • Table 120. France Osteoarthritis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 121. Italy Osteoarthritis Therapeutics, by Type USD Million (2018-2023)
  • Table 122. Italy Osteoarthritis Therapeutics, by Application USD Million (2018-2023)
  • Table 123. Italy Osteoarthritis Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 124. Italy Osteoarthritis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 125. Italy Osteoarthritis Therapeutics, by Sales Channel USD Million (2018-2023)
  • Table 126. Italy Osteoarthritis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 127. United Kingdom Osteoarthritis Therapeutics, by Type USD Million (2018-2023)
  • Table 128. United Kingdom Osteoarthritis Therapeutics, by Application USD Million (2018-2023)
  • Table 129. United Kingdom Osteoarthritis Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 130. United Kingdom Osteoarthritis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 131. United Kingdom Osteoarthritis Therapeutics, by Sales Channel USD Million (2018-2023)
  • Table 132. United Kingdom Osteoarthritis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 133. Netherlands Osteoarthritis Therapeutics, by Type USD Million (2018-2023)
  • Table 134. Netherlands Osteoarthritis Therapeutics, by Application USD Million (2018-2023)
  • Table 135. Netherlands Osteoarthritis Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 136. Netherlands Osteoarthritis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 137. Netherlands Osteoarthritis Therapeutics, by Sales Channel USD Million (2018-2023)
  • Table 138. Netherlands Osteoarthritis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 139. Rest of Europe Osteoarthritis Therapeutics, by Type USD Million (2018-2023)
  • Table 140. Rest of Europe Osteoarthritis Therapeutics, by Application USD Million (2018-2023)
  • Table 141. Rest of Europe Osteoarthritis Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 142. Rest of Europe Osteoarthritis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 143. Rest of Europe Osteoarthritis Therapeutics, by Sales Channel USD Million (2018-2023)
  • Table 144. Rest of Europe Osteoarthritis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 145. MEA Osteoarthritis Therapeutics, by Country USD Million (2018-2023)
  • Table 146. MEA Osteoarthritis Therapeutics, by Type USD Million (2018-2023)
  • Table 147. MEA Osteoarthritis Therapeutics, by Application USD Million (2018-2023)
  • Table 148. MEA Osteoarthritis Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 149. MEA Osteoarthritis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 150. MEA Osteoarthritis Therapeutics, by Sales Channel USD Million (2018-2023)
  • Table 151. MEA Osteoarthritis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 152. Middle East Osteoarthritis Therapeutics, by Type USD Million (2018-2023)
  • Table 153. Middle East Osteoarthritis Therapeutics, by Application USD Million (2018-2023)
  • Table 154. Middle East Osteoarthritis Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 155. Middle East Osteoarthritis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 156. Middle East Osteoarthritis Therapeutics, by Sales Channel USD Million (2018-2023)
  • Table 157. Middle East Osteoarthritis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 158. Africa Osteoarthritis Therapeutics, by Type USD Million (2018-2023)
  • Table 159. Africa Osteoarthritis Therapeutics, by Application USD Million (2018-2023)
  • Table 160. Africa Osteoarthritis Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 161. Africa Osteoarthritis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 162. Africa Osteoarthritis Therapeutics, by Sales Channel USD Million (2018-2023)
  • Table 163. Africa Osteoarthritis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 164. North America Osteoarthritis Therapeutics, by Country USD Million (2018-2023)
  • Table 165. North America Osteoarthritis Therapeutics, by Type USD Million (2018-2023)
  • Table 166. North America Osteoarthritis Therapeutics, by Application USD Million (2018-2023)
  • Table 167. North America Osteoarthritis Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 168. North America Osteoarthritis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 169. North America Osteoarthritis Therapeutics, by Sales Channel USD Million (2018-2023)
  • Table 170. North America Osteoarthritis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 171. United States Osteoarthritis Therapeutics, by Type USD Million (2018-2023)
  • Table 172. United States Osteoarthritis Therapeutics, by Application USD Million (2018-2023)
  • Table 173. United States Osteoarthritis Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 174. United States Osteoarthritis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 175. United States Osteoarthritis Therapeutics, by Sales Channel USD Million (2018-2023)
  • Table 176. United States Osteoarthritis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 177. Canada Osteoarthritis Therapeutics, by Type USD Million (2018-2023)
  • Table 178. Canada Osteoarthritis Therapeutics, by Application USD Million (2018-2023)
  • Table 179. Canada Osteoarthritis Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 180. Canada Osteoarthritis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 181. Canada Osteoarthritis Therapeutics, by Sales Channel USD Million (2018-2023)
  • Table 182. Canada Osteoarthritis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 183. Mexico Osteoarthritis Therapeutics, by Type USD Million (2018-2023)
  • Table 184. Mexico Osteoarthritis Therapeutics, by Application USD Million (2018-2023)
  • Table 185. Mexico Osteoarthritis Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 186. Mexico Osteoarthritis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 187. Mexico Osteoarthritis Therapeutics, by Sales Channel USD Million (2018-2023)
  • Table 188. Mexico Osteoarthritis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 189. Company Basic Information, Sales Area and Its Competitors
  • Table 190. Company Basic Information, Sales Area and Its Competitors
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Osteoarthritis Therapeutics: by Type(USD Million)
  • Table 200. Osteoarthritis Therapeutics Primary osteoarthritis , by Region USD Million (2025-2030)
  • Table 201. Osteoarthritis Therapeutics Secondary osteoarthritis , by Region USD Million (2025-2030)
  • Table 202. Osteoarthritis Therapeutics: by Application(USD Million)
  • Table 203. Osteoarthritis Therapeutics Lifestyle changes. Exercise , by Region USD Million (2025-2030)
  • Table 204. Osteoarthritis Therapeutics Pain relief medicines , by Region USD Million (2025-2030)
  • Table 205. Osteoarthritis Therapeutics Supportive treatments , by Region USD Million (2025-2030)
  • Table 206. Osteoarthritis Therapeutics Surgery , by Region USD Million (2025-2030)
  • Table 207. Osteoarthritis Therapeutics Complementary and alternative therapies , by Region USD Million (2025-2030)
  • Table 208. Osteoarthritis Therapeutics: by Drug Type(USD Million)
  • Table 209. Osteoarthritis Therapeutics Prescription Drugs , by Region USD Million (2025-2030)
  • Table 210. Osteoarthritis Therapeutics Over-the-Counter Drugs , by Region USD Million (2025-2030)
  • Table 211. Osteoarthritis Therapeutics: by Route of Administration(USD Million)
  • Table 212. Osteoarthritis Therapeutics Parenteral Route , by Region USD Million (2025-2030)
  • Table 213. Osteoarthritis Therapeutics Topical Route , by Region USD Million (2025-2030)
  • Table 214. Osteoarthritis Therapeutics Oral Route , by Region USD Million (2025-2030)
  • Table 215. Osteoarthritis Therapeutics: by Sales Channel(USD Million)
  • Table 216. Osteoarthritis Therapeutics Hospital Pharmacies , by Region USD Million (2025-2030)
  • Table 217. Osteoarthritis Therapeutics Retail Pharmacies , by Region USD Million (2025-2030)
  • Table 218. Osteoarthritis Therapeutics Online Pharmacies , by Region USD Million (2025-2030)
  • Table 219. Osteoarthritis Therapeutics: by Anatomy(USD Million)
  • Table 220. Osteoarthritis Therapeutics Knee Osteoarthritis , by Region USD Million (2025-2030)
  • Table 221. Osteoarthritis Therapeutics Hip Osteoarthritis , by Region USD Million (2025-2030)
  • Table 222. Osteoarthritis Therapeutics Hand Osteoarthritis , by Region USD Million (2025-2030)
  • Table 223. Osteoarthritis Therapeutics Small Joint Osteoarthritis , by Region USD Million (2025-2030)
  • Table 224. Osteoarthritis Therapeutics Shoulder Osteoarthritis , by Region USD Million (2025-2030)
  • Table 225. Osteoarthritis Therapeutics Other , by Region USD Million (2025-2030)
  • Table 226. South America Osteoarthritis Therapeutics, by Country USD Million (2025-2030)
  • Table 227. South America Osteoarthritis Therapeutics, by Type USD Million (2025-2030)
  • Table 228. South America Osteoarthritis Therapeutics, by Application USD Million (2025-2030)
  • Table 229. South America Osteoarthritis Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 230. South America Osteoarthritis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 231. South America Osteoarthritis Therapeutics, by Sales Channel USD Million (2025-2030)
  • Table 232. South America Osteoarthritis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 233. Brazil Osteoarthritis Therapeutics, by Type USD Million (2025-2030)
  • Table 234. Brazil Osteoarthritis Therapeutics, by Application USD Million (2025-2030)
  • Table 235. Brazil Osteoarthritis Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 236. Brazil Osteoarthritis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 237. Brazil Osteoarthritis Therapeutics, by Sales Channel USD Million (2025-2030)
  • Table 238. Brazil Osteoarthritis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 239. Argentina Osteoarthritis Therapeutics, by Type USD Million (2025-2030)
  • Table 240. Argentina Osteoarthritis Therapeutics, by Application USD Million (2025-2030)
  • Table 241. Argentina Osteoarthritis Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 242. Argentina Osteoarthritis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 243. Argentina Osteoarthritis Therapeutics, by Sales Channel USD Million (2025-2030)
  • Table 244. Argentina Osteoarthritis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 245. Rest of South America Osteoarthritis Therapeutics, by Type USD Million (2025-2030)
  • Table 246. Rest of South America Osteoarthritis Therapeutics, by Application USD Million (2025-2030)
  • Table 247. Rest of South America Osteoarthritis Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 248. Rest of South America Osteoarthritis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 249. Rest of South America Osteoarthritis Therapeutics, by Sales Channel USD Million (2025-2030)
  • Table 250. Rest of South America Osteoarthritis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 251. Asia Pacific Osteoarthritis Therapeutics, by Country USD Million (2025-2030)
  • Table 252. Asia Pacific Osteoarthritis Therapeutics, by Type USD Million (2025-2030)
  • Table 253. Asia Pacific Osteoarthritis Therapeutics, by Application USD Million (2025-2030)
  • Table 254. Asia Pacific Osteoarthritis Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 255. Asia Pacific Osteoarthritis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 256. Asia Pacific Osteoarthritis Therapeutics, by Sales Channel USD Million (2025-2030)
  • Table 257. Asia Pacific Osteoarthritis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 258. China Osteoarthritis Therapeutics, by Type USD Million (2025-2030)
  • Table 259. China Osteoarthritis Therapeutics, by Application USD Million (2025-2030)
  • Table 260. China Osteoarthritis Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 261. China Osteoarthritis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 262. China Osteoarthritis Therapeutics, by Sales Channel USD Million (2025-2030)
  • Table 263. China Osteoarthritis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 264. Japan Osteoarthritis Therapeutics, by Type USD Million (2025-2030)
  • Table 265. Japan Osteoarthritis Therapeutics, by Application USD Million (2025-2030)
  • Table 266. Japan Osteoarthritis Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 267. Japan Osteoarthritis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 268. Japan Osteoarthritis Therapeutics, by Sales Channel USD Million (2025-2030)
  • Table 269. Japan Osteoarthritis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 270. India Osteoarthritis Therapeutics, by Type USD Million (2025-2030)
  • Table 271. India Osteoarthritis Therapeutics, by Application USD Million (2025-2030)
  • Table 272. India Osteoarthritis Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 273. India Osteoarthritis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 274. India Osteoarthritis Therapeutics, by Sales Channel USD Million (2025-2030)
  • Table 275. India Osteoarthritis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 276. South Korea Osteoarthritis Therapeutics, by Type USD Million (2025-2030)
  • Table 277. South Korea Osteoarthritis Therapeutics, by Application USD Million (2025-2030)
  • Table 278. South Korea Osteoarthritis Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 279. South Korea Osteoarthritis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 280. South Korea Osteoarthritis Therapeutics, by Sales Channel USD Million (2025-2030)
  • Table 281. South Korea Osteoarthritis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 282. Taiwan Osteoarthritis Therapeutics, by Type USD Million (2025-2030)
  • Table 283. Taiwan Osteoarthritis Therapeutics, by Application USD Million (2025-2030)
  • Table 284. Taiwan Osteoarthritis Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 285. Taiwan Osteoarthritis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 286. Taiwan Osteoarthritis Therapeutics, by Sales Channel USD Million (2025-2030)
  • Table 287. Taiwan Osteoarthritis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 288. Australia Osteoarthritis Therapeutics, by Type USD Million (2025-2030)
  • Table 289. Australia Osteoarthritis Therapeutics, by Application USD Million (2025-2030)
  • Table 290. Australia Osteoarthritis Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 291. Australia Osteoarthritis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 292. Australia Osteoarthritis Therapeutics, by Sales Channel USD Million (2025-2030)
  • Table 293. Australia Osteoarthritis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 294. Rest of Asia-Pacific Osteoarthritis Therapeutics, by Type USD Million (2025-2030)
  • Table 295. Rest of Asia-Pacific Osteoarthritis Therapeutics, by Application USD Million (2025-2030)
  • Table 296. Rest of Asia-Pacific Osteoarthritis Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 297. Rest of Asia-Pacific Osteoarthritis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 298. Rest of Asia-Pacific Osteoarthritis Therapeutics, by Sales Channel USD Million (2025-2030)
  • Table 299. Rest of Asia-Pacific Osteoarthritis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 300. Europe Osteoarthritis Therapeutics, by Country USD Million (2025-2030)
  • Table 301. Europe Osteoarthritis Therapeutics, by Type USD Million (2025-2030)
  • Table 302. Europe Osteoarthritis Therapeutics, by Application USD Million (2025-2030)
  • Table 303. Europe Osteoarthritis Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 304. Europe Osteoarthritis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 305. Europe Osteoarthritis Therapeutics, by Sales Channel USD Million (2025-2030)
  • Table 306. Europe Osteoarthritis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 307. Germany Osteoarthritis Therapeutics, by Type USD Million (2025-2030)
  • Table 308. Germany Osteoarthritis Therapeutics, by Application USD Million (2025-2030)
  • Table 309. Germany Osteoarthritis Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 310. Germany Osteoarthritis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 311. Germany Osteoarthritis Therapeutics, by Sales Channel USD Million (2025-2030)
  • Table 312. Germany Osteoarthritis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 313. France Osteoarthritis Therapeutics, by Type USD Million (2025-2030)
  • Table 314. France Osteoarthritis Therapeutics, by Application USD Million (2025-2030)
  • Table 315. France Osteoarthritis Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 316. France Osteoarthritis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 317. France Osteoarthritis Therapeutics, by Sales Channel USD Million (2025-2030)
  • Table 318. France Osteoarthritis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 319. Italy Osteoarthritis Therapeutics, by Type USD Million (2025-2030)
  • Table 320. Italy Osteoarthritis Therapeutics, by Application USD Million (2025-2030)
  • Table 321. Italy Osteoarthritis Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 322. Italy Osteoarthritis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 323. Italy Osteoarthritis Therapeutics, by Sales Channel USD Million (2025-2030)
  • Table 324. Italy Osteoarthritis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 325. United Kingdom Osteoarthritis Therapeutics, by Type USD Million (2025-2030)
  • Table 326. United Kingdom Osteoarthritis Therapeutics, by Application USD Million (2025-2030)
  • Table 327. United Kingdom Osteoarthritis Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 328. United Kingdom Osteoarthritis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 329. United Kingdom Osteoarthritis Therapeutics, by Sales Channel USD Million (2025-2030)
  • Table 330. United Kingdom Osteoarthritis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 331. Netherlands Osteoarthritis Therapeutics, by Type USD Million (2025-2030)
  • Table 332. Netherlands Osteoarthritis Therapeutics, by Application USD Million (2025-2030)
  • Table 333. Netherlands Osteoarthritis Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 334. Netherlands Osteoarthritis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 335. Netherlands Osteoarthritis Therapeutics, by Sales Channel USD Million (2025-2030)
  • Table 336. Netherlands Osteoarthritis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 337. Rest of Europe Osteoarthritis Therapeutics, by Type USD Million (2025-2030)
  • Table 338. Rest of Europe Osteoarthritis Therapeutics, by Application USD Million (2025-2030)
  • Table 339. Rest of Europe Osteoarthritis Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 340. Rest of Europe Osteoarthritis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 341. Rest of Europe Osteoarthritis Therapeutics, by Sales Channel USD Million (2025-2030)
  • Table 342. Rest of Europe Osteoarthritis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 343. MEA Osteoarthritis Therapeutics, by Country USD Million (2025-2030)
  • Table 344. MEA Osteoarthritis Therapeutics, by Type USD Million (2025-2030)
  • Table 345. MEA Osteoarthritis Therapeutics, by Application USD Million (2025-2030)
  • Table 346. MEA Osteoarthritis Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 347. MEA Osteoarthritis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 348. MEA Osteoarthritis Therapeutics, by Sales Channel USD Million (2025-2030)
  • Table 349. MEA Osteoarthritis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 350. Middle East Osteoarthritis Therapeutics, by Type USD Million (2025-2030)
  • Table 351. Middle East Osteoarthritis Therapeutics, by Application USD Million (2025-2030)
  • Table 352. Middle East Osteoarthritis Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 353. Middle East Osteoarthritis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 354. Middle East Osteoarthritis Therapeutics, by Sales Channel USD Million (2025-2030)
  • Table 355. Middle East Osteoarthritis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 356. Africa Osteoarthritis Therapeutics, by Type USD Million (2025-2030)
  • Table 357. Africa Osteoarthritis Therapeutics, by Application USD Million (2025-2030)
  • Table 358. Africa Osteoarthritis Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 359. Africa Osteoarthritis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 360. Africa Osteoarthritis Therapeutics, by Sales Channel USD Million (2025-2030)
  • Table 361. Africa Osteoarthritis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 362. North America Osteoarthritis Therapeutics, by Country USD Million (2025-2030)
  • Table 363. North America Osteoarthritis Therapeutics, by Type USD Million (2025-2030)
  • Table 364. North America Osteoarthritis Therapeutics, by Application USD Million (2025-2030)
  • Table 365. North America Osteoarthritis Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 366. North America Osteoarthritis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 367. North America Osteoarthritis Therapeutics, by Sales Channel USD Million (2025-2030)
  • Table 368. North America Osteoarthritis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 369. United States Osteoarthritis Therapeutics, by Type USD Million (2025-2030)
  • Table 370. United States Osteoarthritis Therapeutics, by Application USD Million (2025-2030)
  • Table 371. United States Osteoarthritis Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 372. United States Osteoarthritis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 373. United States Osteoarthritis Therapeutics, by Sales Channel USD Million (2025-2030)
  • Table 374. United States Osteoarthritis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 375. Canada Osteoarthritis Therapeutics, by Type USD Million (2025-2030)
  • Table 376. Canada Osteoarthritis Therapeutics, by Application USD Million (2025-2030)
  • Table 377. Canada Osteoarthritis Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 378. Canada Osteoarthritis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 379. Canada Osteoarthritis Therapeutics, by Sales Channel USD Million (2025-2030)
  • Table 380. Canada Osteoarthritis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 381. Mexico Osteoarthritis Therapeutics, by Type USD Million (2025-2030)
  • Table 382. Mexico Osteoarthritis Therapeutics, by Application USD Million (2025-2030)
  • Table 383. Mexico Osteoarthritis Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 384. Mexico Osteoarthritis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 385. Mexico Osteoarthritis Therapeutics, by Sales Channel USD Million (2025-2030)
  • Table 386. Mexico Osteoarthritis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 387. Research Programs/Design for This Report
  • Table 388. Key Data Information from Secondary Sources
  • Table 389. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Osteoarthritis Therapeutics: by Type USD Million (2018-2023)
  • Figure 5. Global Osteoarthritis Therapeutics: by Application USD Million (2018-2023)
  • Figure 6. Global Osteoarthritis Therapeutics: by Drug Type USD Million (2018-2023)
  • Figure 7. Global Osteoarthritis Therapeutics: by Route of Administration USD Million (2018-2023)
  • Figure 8. Global Osteoarthritis Therapeutics: by Sales Channel USD Million (2018-2023)
  • Figure 9. Global Osteoarthritis Therapeutics: by Anatomy USD Million (2018-2023)
  • Figure 10. South America Osteoarthritis Therapeutics Share (%), by Country
  • Figure 11. Asia Pacific Osteoarthritis Therapeutics Share (%), by Country
  • Figure 12. Europe Osteoarthritis Therapeutics Share (%), by Country
  • Figure 13. MEA Osteoarthritis Therapeutics Share (%), by Country
  • Figure 14. North America Osteoarthritis Therapeutics Share (%), by Country
  • Figure 15. Global Osteoarthritis Therapeutics share by Players 2023 (%)
  • Figure 16. Global Osteoarthritis Therapeutics share by Players (Top 3) 2023(%)
  • Figure 17. Global Osteoarthritis Therapeutics share by Players (Top 5) 2023(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 20. Sanofi (France) Revenue: by Geography 2023
  • Figure 21. Horizon Therapeutics PLC (Ireland) Revenue, Net Income and Gross profit
  • Figure 22. Horizon Therapeutics PLC (Ireland) Revenue: by Geography 2023
  • Figure 23. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 24. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 25. GlaxoSmithKline PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 26. GlaxoSmithKline PLC (United Kingdom) Revenue: by Geography 2023
  • Figure 27. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Bayer AG (Germany) Revenue: by Geography 2023
  • Figure 29. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 30. Abbott (United States) Revenue: by Geography 2023
  • Figure 31. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Pfizer, Inc. (United States) Revenue: by Geography 2023
  • Figure 33. Eli Lilly (United States) Revenue, Net Income and Gross profit
  • Figure 34. Eli Lilly (United States) Revenue: by Geography 2023
  • Figure 35. Anika Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Anika Therapeutics, Inc. (United States) Revenue: by Geography 2023
  • Figure 37. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 38. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 39. Global Osteoarthritis Therapeutics: by Type USD Million (2025-2030)
  • Figure 40. Global Osteoarthritis Therapeutics: by Application USD Million (2025-2030)
  • Figure 41. Global Osteoarthritis Therapeutics: by Drug Type USD Million (2025-2030)
  • Figure 42. Global Osteoarthritis Therapeutics: by Route of Administration USD Million (2025-2030)
  • Figure 43. Global Osteoarthritis Therapeutics: by Sales Channel USD Million (2025-2030)
  • Figure 44. Global Osteoarthritis Therapeutics: by Anatomy USD Million (2025-2030)
  • Figure 45. South America Osteoarthritis Therapeutics Share (%), by Country
  • Figure 46. Asia Pacific Osteoarthritis Therapeutics Share (%), by Country
  • Figure 47. Europe Osteoarthritis Therapeutics Share (%), by Country
  • Figure 48. MEA Osteoarthritis Therapeutics Share (%), by Country
  • Figure 49. North America Osteoarthritis Therapeutics Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Sanofi (France)
  • Horizon Therapeutics PLC (Ireland)
  • Johnson & Johnson (United States)
  • GlaxoSmithKline PLC (United Kingdom)
  • Bayer AG (Germany)
  • Abbott (United States)
  • Pfizer, Inc. (United States)
  • Eli Lilly (United States)
  • Anika Therapeutics, Inc. (United States)
  • Novartis AG (Switzerland)
Additional players considered in the study are as follows:
Ferring Pharmaceuticals (Switzerland) , Bioventus (United States) , Zimmer Biomet Holdings, Inc. (United States) , Fidia Farmaceutici s.p.a. (Italy) , Pharmed Limited (India) , Hanmi Pharm. Co., Ltd. (Korea) , Laboratorio Reig Jofre (Spain)
Select User Access Type

Key Highlights of Report


Feb 2024 235 Pages 78 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Osteoarthritis Therapeutics Market Quantitative research analysis
Global Osteoarthritis Therapeutics Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Sanofi (France), Horizon Therapeutics PLC (Ireland), Johnson & Johnson (United States), GlaxoSmithKline PLC (United Kingdom), Bayer AG (Germany), Abbott (United States), Pfizer, Inc. (United States), Eli Lilly (United States), Anika Therapeutics, Inc. (United States) and Novartis AG (Switzerland) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Personalized Medicines For Osteoarthritis" is seen as one of major influencing trends for Osteoarthritis Therapeutics Market during projected period 2023-2030.
The Osteoarthritis Therapeutics market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Osteoarthritis Therapeutics Market Report?

Have a Query? Click Here

Other Related Reports

Arthritis Therapeutics Comprehensive Study by Application (Hospital and Healthcare, Pharmaceutical Industry), Route of Administration (Oral, Parenteral, Topical), Sales Channel (Hospital Pharmacies, ...
$ 3750
Autoimmune Hepatitis Treatment Comprehensive Study by Disease Type (Type 1 autoimmune hepatitis, Type 2 autoimmune hepatitis), Treatment (Immunosuppressant Drugs (Corticosteroids), Liver Transplant),...
$ 3750
Diabetic Foot Ulcer Treatment Comprehensive Study by Type (Wound Care Dressings (Alginate Dressings, Hydrofiber Dressings, Foam Dressings, Film Dressing, Hydrocolloid Dressings, Surgical Dressings, H...
$ 3750
Polycystic Ovarian Syndrome Treatment Comprehensive Study by Treatment (Drug Class (Insulin Sensitizing Agent, Oral Contraceptive, Antiandrogens, Anti-Obesity Drugs and Others), Surgery (Ovarian Wedg...
$ 3750
Androgenetic Alopecia Treatment Comprehensive Study by Type (Drugs (Minoxidil, Dutasteride, Finasteride and Others), Low-level Laser Therapy, Microneedling and Hair Transplantation, Others), Distribu...
$ 3650
Tumor Lysis Syndrome Comprehensive Study by Treatment (Medications (allopurinol, rasburicase, sodium bicarbonate or acetazolamide, oral kinase inhibitors and B-cell lymphoma-2 protein inhibitors), Ki...
$ 3650